<!DOCTYPE html>
<html lang="en">
<head id="Head1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <meta http-equiv="content-type" content="text/html;charset=utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=Edge" />
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Full Text of HB1443</title>
    <link rel="shortcut icon" type="image/x-icon" href="https://cdn.ilga.gov/assets/img/site/favicon.ico" />
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap.min.css" />
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <script src="https://cdn.ilga.gov/assets/js/fontawesome/fa.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/jquery.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/js.cookie.min.js"></script>
    <script async src="https://cse.google.com/cse.js?cx=a47f92b5e11c1499a"></script> 
    <!-- Bootstrap Datepicker CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap-datepicker.min.css">
    <!-- Bootstrap Datepicker JavaScript -->
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap-datepicker.min.js"></script>
    <!-- aos, bootstrap icons, swiper CSS -->
    <link href="https://cdn.ilga.gov/assets/css/aos/aos.css" rel="stylesheet">
    <link href="https://cdn.ilga.gov/assets/css/swiper/swiper-bundle.min.css" rel="stylesheet">

    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.js"></script>

    <!-- ILGA main CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/main.css" />
    <link rel="stylesheet" type="text/css" media="print" href="https://cdn.ilga.gov/assets/css/print.css">
    <style></style>
    
</head>
<body>
        <!-- ======= Header ======= -->
        <header id="print-header" class="d-flex align-items-center">
            <div class="container-fluid align-items-center text-uppercase justify-content-start ">
                <div class="logo ">
                    <a href="/"><img src="https://cdn.ilga.gov/assets/img/site/white_capitol.png" alt="ILGA Logo"><span>ILGA.GOV</span></a>
                </div>
                <div class="w-100"></div>
            </div>
        </header>
    <input id="TextSearch" type="hidden" />
    <input id="MobileTextSearch" type="hidden" />
    <input id="message-input" type="hidden" />

    <main id="main-content" role="main">
        <section class="main-page p-2">
	<div class="p-1 pt-4 float-left">
		<div class="row border-bottom pb-3 mb-3">
			<div class="text-start">
				<h2>
					HB1443 - 104th General Assembly
				</h2><br />
			</div>
		</div>
		<div id="content">
			<!-- Full text only shows on large screens -->
			<div class="centered-container d-lg-flex">
				<div class="left-aligned-content">
					<div class="row">
						<div class="col pl-lg-5" translate="no">
							<text class="ml-5 text-left fulltextLineHeight" id="billtextanchor">
								<style>
								
								
								
								table.xsl	{ 	border-collapse: collapse;
												border: 0px solid black;
												font-family: "courier New"; 
												font-size: 10pt;}
								
								td.xsl		{ 	border-collapse: collapse;
												border: 0px solid black;
												padding-top: 3pt;
												padding-bottom: 3pt;
												padding-left: 0pt;
												padding-right: 0pt;
												font-family: "courier New"; 
												font-size: 10pt; }
												
								td.junk		{ 	width: 5%; }
								 
							
					
					
						body.xsl		{ 	text-align:center; }
						
					
						td.lineNum 		{ 	vertical-align: top; 
										  	text-align: right;
										  	font-family: "courier New"; 
										  	font-size: 10pt; }
							
						td.number 		{	width: 5%;
											vertical-align: top; 
										  	text-align: right;
										  	font-family: "Courier New", sans-serif;
										  	font-size: 10pt; }
						
						td.synopsis		{ 	border-collapse: collapse;
											border: 0px solid black;
											padding-top: 0pt;
											padding-bottom: 0pt;
											padding-left: 0pt;
											padding-right: 0pt;
											font-family: "courier New"; 
											font-size: 10pt; }
						
						td.rowsep		{ 	border-bottom: 1px solid black; }
											
						td.colsep		{ 	border-right: 1px solid black; }
											
						td.bothsep		{ 	border-right: 1px solid black;
										  	border-bottom: 1px solid black; }
	
						table.top		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black; }
											
						table.bottom	{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-bottom: 1px solid black; }
											
						table.sides		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black; }
	
						table.all		{ 	font-family: "Courier New", sans-serif;
										  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black;
									  	  	border-bottom: 1px solid black;
									  	  	border-top: 1px solid black; }				
	
						table.topbot	{ 	border-collapse: separate;
									  	  	border: outset 0pt;
										  	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black;
									  	  	border-bottom: 1px solid black; }
					
						.sigline		{ 	text-align: left;
							 		 		vertical-align: bottom;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.siglinetext		{ 	text-align: left;
							 		 		vertical-align: top;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.sigtitle		{ 	text-align: left;
							 				vertical-align: top;
							 				padding: 0pt; }
							 				  
						.sigtitlenum		{ 	text-align: right;
							 				vertical-align: top;
							 				padding: 0pt; }
							
						.siglinenum		{ 	text-align: right;
							 				vertical-align: center;
							 				padding-top: 3pt;
							 				padding: 0pt; }
					</style><table class="xsl" width="578"><pre><tr><td class="xsl" colspan="3"><p> </p><br> </td></tr></td></tr><tr><td class="number"></td><td class="junk"></td><td class="xsl"><table class="xsl" width="100%"><tr><td class="xsl"><center><b><pre><font size="3" face="Courier New">104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026</font><br>HB1443</pre></b></center><p> </p>Introduced 1/28/2025, by Rep. Nabeela Syed<p> </p><b>SYNOPSIS AS INTRODUCED:</b><br> </td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><table class="xsl" width="100%"><colgroup width="50%"></colgroup><colgroup width="50%"></colgroup><tr><td class="synopsis"><code>New Act</code></td><td class="synopsis"></td></tr><tr><td class="synopsis"><code>30 ILCS 105/5.1030 new</code></td><td class="synopsis"></td></tr></table><p></p></td></tr><tr><td class="xsl"><code>    </code><code>Creates the Health Care Availability and Access Board Act. </code><code>Establishes the Health Care Availability and Access Board to protect State </code><code>residents, State and local governments, commercial health plans, health </code><code>care providers, pharmacies licensed in the State, and other stakeholders </code><code>within the health care system from the high costs of prescription drug </code><code>products. Contains provisions concerning Board membership and terms; staff </code><code>for the Board; Board meetings; circumstances under which Board members </code><code>must recuse themselves; and other matters. Provides that the Board shall </code><code>perform the following actions in open session: (i) deliberations on </code><code>whether to subject a prescription drug product to a cost review; and (ii) </code><code>any vote on whether to impose an upper payment limit on purchases, </code><code>payments, and payor reimbursements of prescription drug products in the </code><code>State. Permits the Board to adopt rules to implement the Act and to enter </code><code>into a contract with a qualified, independent third party for any service </code><code>necessary to carry out the powers and duties of the Board. Creates the </code><code>Health Care Availability and Access Stakeholder Council to provide </code><code>stakeholder input to assist the Board in making decisions as required by </code><code>the Act. Contains provisions concerning Council membership, member terms, </code><code>and other matters. Provides that the Board shall adopt the federal </code><code>Medicare Maximum Fair Price as the upper payment limit for a prescription </code><code>drug product intended for use by individuals in the State. Prohibits the </code><code>Board from creating an upper payment limit that is different from the </code><code>Medicare Maximum Fair Price for the prescription drug product that has a </code><code>Medicare Maximum Fair Price. Requires the Board to implement an upper </code><code>payment limit that is the same as the Medicare Maximum Fair Price no sooner </code><code>than the Medicare implementation date. Provides that Medicare Part C and D </code><code>plans are not required to reimburse at the upper payment limit. Provides </code><code>that the Attorney General may enforce the Act and may pursue any available </code><code>remedy under State law when enforcing the Act. Effective 180 days after </code><code>becoming law.</code></td></tr><tr align="right" class="lineNum"><td class="xsl"><br><br></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left"></td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><p> </p><p> </p><center><b>A BILL FOR</b></center><p></p></td></tr></table><p> </p></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>AN ACT concerning health.</code><br> </td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><b><code>Be it enacted by the People of the State of Illinois, </code></b></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><b><code>represented in the General Assembly:</code></b><br> </td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 1. </code><code>Short title. </code><code>This Act may be cited as the </code><code>Health </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>Care Availability and Access Board Act.</code><br> </td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 5. </code><code>Definitions. </code><code>In this Act:</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Biologic" means a drug that is produced or distributed in </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>accordance with a biologics license application approved under </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>42 U.S.C. 262(k)(3). </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Biosimilar" means a drug that is produced or distributed </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>in accordance with a biologics license application approved </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>under 42 U.S.C. 262(k)(3).</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Board" means the Health Care Availability and Access </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>Board.</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Brand name drug" means a drug that is produced or </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>distributed in accordance with an original new drug </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>application approved under 21 U.S.C. 355(c). "Brand name drug" </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>does not include an authorized generic drug as defined by 42 </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>CFR 447.502.</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Council" means the Health Care Availability and Access </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>Stakeholder Council.</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Generic drug" means:</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) a retail drug that is marketed or distributed in </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center">- 2 -</td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>accordance with an abbreviated new drug application, </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>approved under 21 U.S.C. 355(j);</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) an authorized generic drug as defined by 42 CFR </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>447.502; or</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) a drug that entered the market before 1962 that </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>was not originally marketed under a new drug application. </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Manufacturer" means an entity that:</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) owns the patent to a prescription drug product; or</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) enters into a lease with another manufacturer to </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>market and distribute a prescription drug product under </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>the entity's own name;</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) is the labeled entity of the generic product at </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>the point of manufacture; and</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) sets or changes the wholesale acquisition cost of </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>the prescription drug product it manufactures or markets.</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Prescription drug product" means a brand name drug, a </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>generic drug, a biologic, or a biosimilar. </code><br> </td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 10. </code><code>Health Care Availability and Access Board. </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) There is established a Health Care Availability and </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>Access Board. The purpose of the Board is to protect State </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>residents, State and local governments, commercial health </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>plans, health care providers, pharmacies licensed in the </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>State, and other stakeholders within the health care system </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>from the high costs of prescription drug products. The Board </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>is a public body and is an instrumentality of the State. The </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center">- 3 -</td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>Board is an independent unit of State government. The exercise </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>by the Board of its authority under this Act is an essential </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>function. </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b)(1) The 5 members of the Board and 3 alternate members </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>shall be appointed by the Governor with the advice and consent </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>of the Senate.</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(2) The Board membership must include individuals with </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>demonstrated expertise in health care economics, </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>pharmaceutical markets, and clinical medicine. A member or an </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>alternate member may not be an employee of, a Board member of, </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>or a consultant to a manufacturer or trade association for </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>manufacturers.</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(3) Any conflict of interest, including whether the </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>individual has an association, including a financial or </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>personal association, that has the potential to bias or has </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>the appearance of biasing an individual's decision in matters </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>related to the Board or the conduct of the Board's activities, </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>shall be considered and disclosed when appointing members and </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>alternate members to the Board.</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) The term of a member or an alternate member is 5 years, </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>except that the terms of the initial members and alternate </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>members shall be staggered as required by the terms provided </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>for members in Section 55. Board members shall be appointed </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>within 90 days after the effective date of this Act. The Board </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>may begin its work regardless of a delay in appointments to the </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>Health Care Availability and Access Stakeholder Council </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center">- 4 -</td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>created under Section 20.</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) The Chair shall hire an executive director, general </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>counsel, and staff for the Board. Staff of the Board shall </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>receive a salary as provided in the budget of the Board. A </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>member of the Board: (i) may receive compensation as a member </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>of the Board; and (ii) is entitled to reimbursement for </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>expenses.</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) A majority of the members of the Board shall </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>constitute a quorum for the purposes of conducting the </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>business of the Board.</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f) Subject to the requirements of this subsection, the </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>Board shall meet in open session at least 4 times per year to </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>review prescription drug product information. Information </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>concerning the location, date, and time of the meeting must be </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>made publicly available in accordance with the Open Meetings </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>Act. The Chair may cancel or postpone a meeting if there is no </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>business to conduct.</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>The Board shall perform the following actions in open </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>session: (i) deliberations on whether to subject a </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>prescription drug product to a cost review under subsection </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>(f) of Section 25; and (ii) any vote on whether to impose an </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>upper payment limit on purchases, payments, and payor </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>reimbursements of prescription drug products in the State. The </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>Board may otherwise meet in closed session to discuss </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>proprietary data and information.</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>The Board shall provide public notice of each Board </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center">- 5 -</td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>meeting at least 3 weeks in advance of the meeting. Materials </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>for each Board meeting shall be made available to the public at </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>least 3 weeks in advance of the meeting. The Board shall </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>provide an opportunity for public comment at each open meeting </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>of the Board. The Board shall provide the public with the </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>opportunity to provide written comments on pending decisions </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>of the Board. The Board may allow expert testimony at Board </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>meetings, including when the Board meets in closed session.</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(g)(1) Members of the Board shall recuse themselves from </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>decisions related to a prescription drug product if the </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>member, or an immediate family member of the member, has </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>received or could receive any of the following:</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(A) a direct financial benefit of any amount deriving </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>from the result or finding of a study or determination by </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>or for the Board; or</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(B) a financial benefit from any person who owns, </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>manufactures, or provides prescription drug products, </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>services, or items to be studied by the Board that in the </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>aggregate exceeds $5,000 per year.</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>As used in this paragraph, "financial benefit" includes </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>honoraria, fees, stock, the value of the member's or immediate </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>family member's stock holdings, and any direct financial </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>benefit deriving from the finding of a review conducted under </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>this Act.</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(2) A disclosure of interests under this Section shall </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>include the type, nature, and magnitude of the interests of </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center">- 6 -</td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>the member or his or her immediate family member involved.</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(3) A conflict of interest shall be disclosed in advance </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>of the first open meeting after the conflict is identified or </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>within 5 days after the conflict is identified. A conflict of </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>interest shall be disclosed by:</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(A) the Board when hiring Board staff;</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(B) the appointing authority when appointing members </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>and alternate members to the Board and members to the </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>Council; and</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(C) the Board when a member of the Board is recused in </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>any final decision resulting from a review of a </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>prescription drug product.</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(4) A conflict of interest disclosed under this Section </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>shall be posted on the website of the Board unless the Chair of </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>the Board recuses the member from any final decision resulting </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>from a review of a prescription drug product.</code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(5) Members and alternate members of the Board, Board </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>staff, and third-party contractors may not accept any gift or </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>donation of services or property that indicates a potential </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>conflict of interest or has the appearance of biasing the work </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>of the Board.</code><br> </td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 15. </code><code>Powers and duties of the Board. </code><code>In addition to </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>the powers set forth elsewhere in this Act, the Board may:</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) adopt rules for the implementation of this Act; </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>and</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center">- 7 -</td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) enter into a contract with a qualified, </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>independent third party for any service necessary to carry </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>out the powers and duties of the Board.</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Unless permission is granted by the Board, a third party </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>hired by the Board may not release, publish, or otherwise use </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>any information to which the third party has access under its </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>contract.</code><br> </td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 20. </code><code>Health Care Availability and Access </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>Stakeholder Council. </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) The Health Care Availability and Access Stakeholder </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>Council is created. The purpose of the Council is to provide </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>stakeholder input to assist the Board in making decisions as </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>required under this Act. The Council consists of 15 members </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>appointed within 90 days after the effective date of this Act </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>as follows:</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) 3 members appointed by the Speaker of the House of </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>Representatives; </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) 2 members appointed by the Minority Leader of the </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>House of Representatives; </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) 3 members appointed by the President of the </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>Senate; </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) 2 members appointed by the Minority Leader of the </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>Senate; and</code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) 5 members appointed by the Governor.</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) The members of the Council shall have knowledge in one </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center">- 8 -</td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>or more of the following: </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) the pharmaceutical business model;</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) supply chain business models;</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) the practice of medicine or clinical training;</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) consumer or patient perspectives;</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) clinical and health services research; or</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(6) the State's health care marketplace. </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) From among the membership of the Council, the Board </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>Chair shall appoint one member to be Council Chair. </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) The term of a member is 3 years, except that the </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>initial members of the Council shall serve staggered terms as </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>required by the terms provided for members in Section 55. </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) A member of the Council may not receive compensation </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>as a member of the Council, but is entitled to reimbursement </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>for travel expenses.</code><br> </td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 25. </code><code>Drug cost affordability review. </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) The Board shall limit its review of prescription drug </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>products to those that are:</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) brand name drugs or biologics that, as adjusted </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <code>annually for inflation in accordance with the Consumer </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>Price Index, have:</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(A) a wholesale acquisition cost of $60,000 or </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >        <code>more per year or course of treatment if less than a </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >        <code>year; or </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(B) a wholesale acquisition cost increase of </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center">- 9 -</td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >        <code>$3,000 or more in any 12-month period;</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) biosimilar drugs that have a wholesale acquisition </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>cost that is not at least 20% lower than the referenced </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>brand biologic at the time the biosimilars are launched, </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>and that have been suggested for review by the members of </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>public, medical professionals, and other stakeholders;</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) generic drugs that, as adjusted annually for </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>inflation in accordance with the Consumer Price Index, </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>have a wholesale acquisition cost of at least $100 for a </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>30-day supply or course of treatment less than 30 days and </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>which increased by 200% or more during the immediately </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>preceding 12-month period, as determined by the difference </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>between the resulting wholesale acquisition cost and the </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>average of the wholesale acquisition cost reported over </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>the immediately preceding 12 months; and</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) other prescription drug products that may create </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>affordability challenges for the State health care system </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >    <code>or patients, including, but not limited to, drugs to </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <code>address public health emergencies.</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>The Board is not required to identify every prescription </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>drug that meets the criteria of this subsection.</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) The Board shall solicit public input on prescription </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>drugs thought to be creating affordability challenges that </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>meet the parameters of paragraphs (1) through (4) of </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>subsection (a). The Board shall determine whether to conduct a </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>full affordability review for the proposed prescription drugs </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center">- 10 -</td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>after compiling preliminary information about the cost of the </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>product, patient cost sharing for the product, health plan </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>spending on the product, stakeholder input, and other </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>information decided by the Board.</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) If the Board conducts a review of the cost and </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>affordability of a prescription drug product, the review shall </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>determine whether use of the prescription drug product that is </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>fully consistent with the labeling approved by the United </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>States Food and Drug Administration or standard medical </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>practice has led or will lead to affordability challenges for </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>the State health care system or high out-of-pocket costs for </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>patients. </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) The information to conduct an affordability review may </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>include, but is not limited to, any document and research </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>related to the manufacturer's selection of the introductory </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>price or price increase of the prescription drug product, </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>patient assistance program or programs specific to the </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>product, estimated or actual manufacturer product price </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>concessions in the market, net product cost to State payers, </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>and other information as determined by the Board.</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) Failure of a manufacturer to provide the Board with </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>the information for an affordability review does not affect </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>the authority of the Board to conduct such a review. </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f) If the Board finds that the spending on a prescription </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>drug product reviewed under this Section has led or will lead </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>to an affordability challenge, the Board shall establish an </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center">- 11 -</td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>upper payment limit considering exceptional administrative </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>costs related to the distribution of the drug in the State.</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(g) The upper payment limit applies to all purchases and </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>payor reimbursements of the prescription drug product intended </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>for use by individuals in the State, in person, by mail, or by </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>other means.</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(h) Any information submitted to the Board in accordance </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>with this Section shall be subject to public inspection only </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>to the extent allowed under the Freedom of Information Act.</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(i) This Section may not be construed to prevent a </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>manufacturer from marketing a prescription drug product </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>approved by the United States Food and Drug Administration </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>while the product is under review by the Board.</code><br> </td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 30. </code><code>Protections and other Board considerations. </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) The Board shall examine how an upper payment limit </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>would affect a covered entity, as that term is defined in </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>Section 340B of the federal Public Health Service Act.</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) In determining whether a drug creates an affordability </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>challenge or determining an upper payment limit amount, the </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>Board may not use cost-effectiveness analyses that include the </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>cost-per-quality adjusted life year or a similar measure to </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>identify subpopulations for which a treatment would be less </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>cost-effective due to severity of illness, age, or preexisting </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>disability. In addition, for any treatment that extends life, </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>if the Board uses cost-effectiveness results, the Board must </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center">- 12 -</td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>use results that weigh the value of all additional lifetime </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>gained equally for all patients no matter their severity of </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>illness, age, or preexisting disability.</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) An upper payment limit is effective no sooner than 6 </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>months after it has been announced.</code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) State-regulated health plans shall inform the Board of </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>how any upper payment limit-related cost savings are directed </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>to the benefit of enrollees, with a priority on enrollee cost </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>sharing. </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) The upper payment limit shall not be inclusive of the </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>pharmacy dispensing fee or provider administration fee.</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f) State licensed independent pharmacies may not be </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>reimbursed less than the upper payment limit. </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(g) The Board shall adopt the Medicare Maximum Fair Price </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>as defined in 42 U.S.C. 1320f(c)(3) for a prescription drug as </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>the upper payment limit for that prescription drug product </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>intended for use by individuals in this State, per subsection </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>(g) of Section 25.</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(h) The Board shall not create an upper payment limit that </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>is different from the Medicare Maximum Fair Price for the </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>prescription drug product that has a Medicare Maximum Fair </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>Price. </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(i) The Board shall implement an upper payment limit that </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>is the same as the Medicare Maximum Fair Price no sooner than </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>the Medicare implementation date. </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(j) Medicare Part C and D plans are not required to </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center">- 13 -</td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>reimburse at the upper payment limit.</code><br> </td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 35. </code><code>Remedies. </code><code>The Attorney General may enforce </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>this Act. The Attorney General may pursue any available remedy </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>under State law when enforcing this Act.</code><br> </td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 40. </code><code>Appeal of Board decisions. </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) A person aggrieved by a decision of the Board may </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>request an appeal of the decision within 30 days after the </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>finding of the Board.</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) The Board shall hear the appeal and make a final </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>decision within 60 days after the appeal is requested.</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) Any person aggrieved by a final decision of the Board </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>may petition for judicial review in accordance with the </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>provisions of the Administrative Review Law.</code><br> </td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 45. </code><code>Health Care Availability and Access Board </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>Fund. </code><code>The Health Care Availability and Access Board Fund is </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>created as a special fund in the State treasury. The Board </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>shall be funded by an annual assessment on all manufacturers </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>whose products are sold in the State. All funds collected by </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>the Board from the assessments shall be deposited into the </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>Fund. The Fund shall be used only to provide funding for the </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>Board and for the purposes authorized under this Act, </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>including any costs expended by any State agency to implement </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>this Act. All interest earned on moneys in the Fund shall be </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center">- 14 -</td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>credited to the Fund. This Section may not be construed to </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>prohibit the Fund from receiving moneys from any other source </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>that does not create the appearance of a conflict of interest. </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>The Board shall be established using general funds, which </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>shall be repaid to the State with the assessments required </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>under this Section.</code><br> </td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 50. </code><code>Reports. </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) On or before December 31 of each year, the Board shall </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>submit to the General Assembly a report that includes:</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) price trends for prescription drug products;</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) the number of prescription drug products that were </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>subject to Board review, including the results of the </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" >    <code>review and the number and disposition of appeals and </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >    <code>judicial reviews of Board decisions; and</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) any recommendations the Board may have on further </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" >    <code>legislation needed to make prescription drug products more </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >    <code>affordable in this State.</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) On or before June 1, 2025, the Health Care </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>Availability and Access Board shall submit a report to the </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>General Assembly about the operation of the generic drug </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>market in the United States that includes a review of </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>physician-administered drugs and considers:</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) the prices of generic drugs on a year-over-year </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>basis;</code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) the degree to which generic drug prices affect </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center">- 15 -</td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>insurance premiums as reported by health insurers in this </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>State or other states that collect this information;</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) recent and current trends in patient cost sharing </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>for generic drugs;</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) the causes and prevalence of generic drug </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>shortages; and</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) any other relevant study questions.</code><br> </td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 55. </code><code>Term expiration. </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) The terms of the initial members and alternate members </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>of the Health Care Availability and Access Board shall expire </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>as follows:</code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) one member and one alternate member in 2029;</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) 2 members and one alternate member in 2030; and </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) 2 members, including the Chair of the Board, and </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" >    <code>one alternate member in 2031.</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) The terms of the initial members of the Health Care </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>Availability and Access Stakeholder Council shall expire as </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>follows:</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) 5 members in 2029;</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) 5 members in 2030; and</code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) 5 members in 2031.</code><br> </td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 97. </code><code>Severability. </code><code>If any provision of this Act or </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>the application thereof to any person or circumstance is held </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>invalid for any reason in a court of competent jurisdiction, </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB1443</td><td class="xsl" align="center">- 16 -</td><td class="xsl" align="right">LRB104 06394 BAB 16430 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>the invalidity does not affect other provisions or any other </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>application of this Act that can be given effect without the </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>invalid provision or application, and for this purpose the </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>provisions of this Act are declared severable.</code><br> </td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 900. </code><code>The State Finance Act is amended by adding </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>Section 5.1030 as follows:</code><br> </td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(30 ILCS 105/5.1030 new)</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>Sec. 5.1030. </code></u><u><code>The Health Care Availability and Access Board </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><u><code>Fund.</code></u><br> </td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 999. </code><code>Effective date. </code><code>This Act takes effect 180 </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>days after becoming law.</code></pre></table>
							</text>
						</div>
					</div>
				</div>
			</div>
		</div>
    </div>
</section>
    </main>
    <!-- Vendor JS Files -->
    <script src="https://cdn.ilga.gov/assets/js/aos/aos.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/popper.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap.bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/glightbox/glightbox.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/swiper/swiper-bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/main.js"></script>

    

</body>
</html>
